Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient

Drug-induced liver injury (DILI) has not been previously reported as a complication of treatment with everolimus. A 56-year-old Caucasian male liver transplant recipient developed DILI after receiving everolimus. Elevations in transaminase levels occurred within a week of starting everolimus and an...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Serena, Mendler, Michel H., Valasek, Mark A., Tsunoda, Shirley M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076919/
https://www.ncbi.nlm.nih.gov/pubmed/30105113
http://dx.doi.org/10.1155/2018/7410508
_version_ 1783344806117769216
author Patel, Serena
Mendler, Michel H.
Valasek, Mark A.
Tsunoda, Shirley M.
author_facet Patel, Serena
Mendler, Michel H.
Valasek, Mark A.
Tsunoda, Shirley M.
author_sort Patel, Serena
collection PubMed
description Drug-induced liver injury (DILI) has not been previously reported as a complication of treatment with everolimus. A 56-year-old Caucasian male liver transplant recipient developed DILI after receiving everolimus. Elevations in transaminase levels occurred within a week of starting everolimus and an upward trend in the transaminase levels continued with supporting histopathologic changes confirmed by liver biopsy. Within one week of drug discontinuation, his liver enzymes normalized to baseline. This report includes a brief review of the pharmacokinetic properties of everolimus, a review of the relevant literature, and an analysis using the RUCAM and Naranjo algorithms.
format Online
Article
Text
id pubmed-6076919
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-60769192018-08-13 Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient Patel, Serena Mendler, Michel H. Valasek, Mark A. Tsunoda, Shirley M. Case Rep Transplant Case Report Drug-induced liver injury (DILI) has not been previously reported as a complication of treatment with everolimus. A 56-year-old Caucasian male liver transplant recipient developed DILI after receiving everolimus. Elevations in transaminase levels occurred within a week of starting everolimus and an upward trend in the transaminase levels continued with supporting histopathologic changes confirmed by liver biopsy. Within one week of drug discontinuation, his liver enzymes normalized to baseline. This report includes a brief review of the pharmacokinetic properties of everolimus, a review of the relevant literature, and an analysis using the RUCAM and Naranjo algorithms. Hindawi 2018-07-18 /pmc/articles/PMC6076919/ /pubmed/30105113 http://dx.doi.org/10.1155/2018/7410508 Text en Copyright © 2018 Serena Patel et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Patel, Serena
Mendler, Michel H.
Valasek, Mark A.
Tsunoda, Shirley M.
Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient
title Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient
title_full Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient
title_fullStr Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient
title_full_unstemmed Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient
title_short Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient
title_sort drug-induced liver injury associated with the use of everolimus in a liver transplant patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076919/
https://www.ncbi.nlm.nih.gov/pubmed/30105113
http://dx.doi.org/10.1155/2018/7410508
work_keys_str_mv AT patelserena druginducedliverinjuryassociatedwiththeuseofeverolimusinalivertransplantpatient
AT mendlermichelh druginducedliverinjuryassociatedwiththeuseofeverolimusinalivertransplantpatient
AT valasekmarka druginducedliverinjuryassociatedwiththeuseofeverolimusinalivertransplantpatient
AT tsunodashirleym druginducedliverinjuryassociatedwiththeuseofeverolimusinalivertransplantpatient

Ejemplares similares